IMVT vs. SLNO, QGEN, MRNA, ASND, VTRS, BPMC, BBIO, VRNA, ROIV, and ELAN
Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), and Elanco Animal Health (ELAN). These companies are all part of the "medical" sector.
Immunovant vs. Its Competitors
Soleno Therapeutics (NASDAQ:SLNO) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.
97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by insiders. Comparatively, 5.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Soleno Therapeutics had 3 more articles in the media than Immunovant. MarketBeat recorded 6 mentions for Soleno Therapeutics and 3 mentions for Immunovant. Soleno Therapeutics' average media sentiment score of 0.72 beat Immunovant's score of 0.00 indicating that Soleno Therapeutics is being referred to more favorably in the media.
Soleno Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.
Soleno Therapeutics currently has a consensus price target of $107.10, indicating a potential upside of 25.60%. Immunovant has a consensus price target of $38.33, indicating a potential upside of 133.46%. Given Immunovant's higher probable upside, analysts plainly believe Immunovant is more favorable than Soleno Therapeutics.
Soleno Therapeutics has a beta of -2.63, suggesting that its stock price is 363% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
Soleno Therapeutics' return on equity of -77.52% beat Immunovant's return on equity.
Summary
Soleno Therapeutics beats Immunovant on 9 of the 13 factors compared between the two stocks.
Get Immunovant News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunovant Competitors List
Related Companies and Tools
This page (NASDAQ:IMVT) was last updated on 7/8/2025 by MarketBeat.com Staff
